863971-53-3Relevant articles and documents
CANCER VACCINE
-
Page/Page column 50, (2021/03/13)
The invention relates to a combination of a TLR-9 agonist and a conjugate of Formula (I) or pharmaceutically acceptable salt thereof. (Formula (I))
GLYCOPEPTIDE VACCINE
-
Page/Page column 50, (2020/11/30)
The present invention generally relates to a glycopeptide conjugate compound of Formula (I):, as described herein, compositions comprising the conjugate compound and to the use of such a compound to as a vaccine.
SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES
-
Page/Page column 131; 137-138, (2020/05/12)
The present invention relates to a linker of the following formula (I) or a salt thereof: (I). The present invention relates to a linker-drug conjugate of the following formula (II) or a salt thereof: (II). The present invention relates also to a binding unit-drug conjugate, such as an antibody- drug conjugate, of the following formula (III) or (IV) or a salt thereof: (III), (IV), as well as a pharmaceutical composition comprising such a binding unit-drug conjugate and its use in the treatment of cancer.